Gut bacteria drugs and immunotherapy in lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study looks at whether certain drugs (like antibiotics or other gut-bacteria-affecting medications) influence how well immunotherapy works for advanced non-small cell lung cancer. It may help find ways to improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with non-small cell lung cancer (NSCLC).
- Your cancer is stage IV or stage III-C.
- You are currently receiving or have received immunotherapy for your lung cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the bacteria in your gut (microbiome) can affect how well immunotherapy works for lung cancer that can be surgically removed. You may receive immunotherapy or chemotherapy before surgery to shrink the tumor.
This trial studies how gut bacteria (the microbiome) and the body’s immune signs change over time while you receive PD-1–based immunotherapy for advanced, unresectable non–small cell lung cancer. The goal is to learn which immune and microbial patterns might relate to how well treatment works and how patients respond.
This study looks at how your gut bacteria might affect a treatment for lung cancer that combines chemotherapy and immunotherapy before surgery. It aims to see if certain bacteria can help the treatment work better.
This study looks at how the bacteria in your gut (microbiome) might affect how well your lung cancer treatment works and what side effects you experience. The goal is to learn if certain gut bacteria can predict treatment response or side effects for people with advanced non-small cell lung cancer.
This study looks at how the bacteria in your gut may affect how well immunotherapy works for solid cancers that have spread or cannot be removed. It focuses on people who have been on certain immunotherapy drugs (PD-1 or PD-L1 inhibitors) for at least 3 months but less than 2 years.
This trial looks at how the gut microbiome (the bacteria in your digestive system) relates to outcomes when you take standard immune “checkpoint” cancer medicines. If you’re eligible, they’ll collect stool samples while you receive treatment for certain cancers.
Hear when a new Dysbiosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.